Liquid biopsies can match non-small cell lung cancer (NSCLC) patients to life-prolonging targeted therapy CONTEXT: Liquid biopsies can match non-small cell lung cancer (NSCLC) patients to life-prolonging targeted therapy and Continue Reading
Real-World research study reveals less than half of NSCLC patients receive comprehensive biomarker testing prior to receiving 1st line therapy. CONTEXT: A retrospective chart review of metastatic NSCLC patients presented Continue Reading
CONTEXT: Report of two abstracts presented by Lucence at ASCO 2021 detailing their molecular profiling of advanced cancers in a real-world setting using a liquid biopsy assay and results of Continue Reading
CONTEXT: A philanthropy-fuelled database created at the University of Calgary is proving its value and attracting international attention, including for some highly encouraging new research for treating lung cancer (NSCLC) | Cananda only data Continue Reading
CONTEXT: Report of a paper published in Immunotherapy, May 26th 2021 edition describing RWE study of PD-L1 testing patterns and treatment distribution in patients with NSCLC in Israel. The results Continue Reading
CONTEXT: Report of a retrospective cohort study publish in JAMA Network Open describing the use of Keytruda (Pembrolizumab) alone and in combination with chemotherapy in the treatment of NSCLC | Continue Reading
CONTEXT: On the back of previous news stories about genetic biomarker testing in NSCLC, Neogenomics announces the launch of KRAS G12C testing to eligible advanced / late stage NSCLC cancer Continue Reading
